跳至主要内容
临床试验/NCT00168467
NCT00168467已完成4 期

The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

Baker Heart Research Institute2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2005年9月15日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
40
试验地点
2
主要终点
Time to onset of claudication

研究概览

简要总结

One important clinical challenge in older individuals is maintaining mobility in the absence of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility.

Conventional therapies have only modest effect in improving symptoms. The investigators hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
— 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ankle-brachial index of <0.9 at rest in at least one leg
  • History of intermittent claudication (unilateral or bilateral) which was stable for 6 months
  • Evidence of superficial femoral artery stenosis or occlusion on duplex scan
  • Blood pressure <=160/90 mmHg
  • Stable medication regimen for at least 6 months and not previously treated with ACE inhibitors

排除标准

  • Limiting coronary artery disease
  • Renal Failure
  • History of hypertension
  • History of type 2 diabetes mellitus

结局指标

主要结局

Time to onset of claudication

Total exercise time during a standard treadmill test

Walking ability measured using the standard Walking Impairment Questionnaire

次要结局

  • Leg Blood Flow using Duplex Ultrasound

研究者

发起方
Baker Heart Research Institute
申办方类型
Other

研究点 (2)

Loading locations...

相似试验